Anxiety Management in Outpatient Psychiatry

1. Differential Diagnosis

Accurate diagnosis forms the foundation of effective anxiety management. The anxiety disorders share overlapping features but have distinct diagnostic criteria, course patterns, and treatment implications.

Generalized Anxiety Disorder (GAD)

DSM-5 Criteria: Excessive anxiety and worry occurring more days than not for at least 6 months about a number of events or activities. The individual finds it difficult to control the worry.

Associated with three or more of the following symptoms:

• Restlessness or feeling keyed up/on edge
• Being easily fatigued
• Difficulty concentrating or mind going blank
• Irritability
• Muscle tension
• Sleep disturbance

Key distinguishing features: Chronic, pervasive worry across multiple domains; not limited to specific triggers; worry feels uncontrollable; significant functional impairment.

Panic Disorder

DSM-5 Criteria: Recurrent unexpected panic attacks followed by at least one month of:

• Persistent concern about additional attacks or their consequences
• Significant maladaptive change in behavior related to the attacks

Panic attack symptoms (peak within minutes, ≥4 required):

• Palpitations, pounding heart, or accelerated heart rate
• Sweating
• Trembling or shaking
• Sensations of shortness of breath or smothering
• Feelings of choking
• Chest pain or discomfort
• Nausea or abdominal distress
• Dizziness, unsteadiness, lightheadedness, or faintness
• Derealization or depersonalization
• Fear of losing control or "going crazy"
• Fear of dying
• Paresthesias
• Chills or heat sensations

Key distinguishing features: Acute, discrete episodes of intense fear; anticipatory anxiety between attacks; often presents with cardiac complaints in emergency settings.

Social Anxiety Disorder (Social Phobia)

DSM-5 Criteria: Marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others. The individual fears they will act in a way or show anxiety symptoms that will be negatively evaluated.

Key features: Social situations almost always provoke fear or anxiety; feared situations are avoided or endured with intense distress; fear is out of proportion to actual threat.

Performance-only specifier: Limited to speaking or performing in public.

Specific Phobia

DSM-5 Criteria: Marked fear or anxiety about a specific object or situation. The phobic object is actively avoided or endured with intense fear.

Five subtypes:

• Animal: Spiders, insects, dogs
• Natural environment: Heights, storms, water
• Blood-injection-injury: Unique vasovagal response with bradycardia
• Situational: Airplanes, enclosed spaces
• Other: Choking, vomiting, costumed characters

Agoraphobia

DSM-5 Criteria: Marked fear or anxiety about two or more of the following: using public transportation, being in open spaces, being in enclosed places, standing in line or being in a crowd, being outside of the home alone.

Key feature: Fear that escape might be difficult or help unavailable if panic-like symptoms develop. Can occur with or without panic disorder history.

Differential Diagnosis Quick Reference

2. Screening Tools

Validated screening instruments improve detection rates and provide objective measures for tracking treatment response. These tools are not diagnostic but guide clinical assessment.

GAD-7 (Generalized Anxiety Disorder-7)

The most widely used anxiety screening tool in primary care and psychiatric settings.

Psychometric properties: Sensitivity 89%, specificity 82% for GAD diagnosis at cutoff ≥10. Internal consistency α = 0.92.

Administration: Self-report, 2-3 minutes. Items scored 0-3 (not at all to nearly every day).

PHQ-9 (Patient Health Questionnaire-9)

Essential for screening comorbid depression given high GAD-MDD comorbidity.

• Score 0-4: Minimal depression
• Score 5-9: Mild depression
• Score 10-14: Moderate depression
• Score 15-19: Moderately severe depression
• Score 20-27: Severe depression

Critical item: Question 9 (thoughts of self-harm) requires immediate clinical attention if scored >0.

SPIN (Social Phobia Inventory)

17-item self-report measure for social anxiety disorder.

• Items rated 0-4 (not at all to extremely)
• Score range: 0-68
• Cutoff ≥19 indicates clinically significant social anxiety
• Score ≥50 suggests severe social anxiety

Three subscales: fear, avoidance, and physiological symptoms.

PDSS (Panic Disorder Severity Scale)

7-item clinician-administered scale assessing panic frequency, distress, and impairment.

• Each item scored 0-4
• Total score 0-28
• Score ≥8 indicates clinically significant panic disorder
• Score ≥15 suggests moderate-severe panic disorder

HAM-A (Hamilton Anxiety Rating Scale)

14-item clinician-administered scale, gold standard for anxiety severity assessment in research.

• Score 0-17: Mild anxiety
• Score 18-24: Mild-moderate anxiety
• Score 25-30: Moderate-severe anxiety
• Score >30: Severe anxiety

Note: Items 1-6 assess psychic anxiety; items 7-14 assess somatic anxiety. Takes 15-20 minutes to administer.

LSAS (Liebowitz Social Anxiety Scale)

24-item clinician-administered scale for social anxiety severity.

• Assesses fear and avoidance across 24 social situations
• Each rated 0-3 (none to severe/always)
• Total score 0-144
• Score ≥55 indicates generalized social phobia
• Score ≥95 suggests severe social anxiety

3. First-Line Pharmacotherapy

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line pharmacological treatments for anxiety disorders. Effect sizes are moderate to large across anxiety conditions.

SSRIs (Selective Serotonin Reuptake Inhibitors)

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Treatment Principles

• Onset of benefit: 2-6 weeks for initial improvement; full therapeutic effect may require 8-12 weeks
• Start low, go slow: Begin with half the usual starting dose for panic disorder (higher sensitivity to activation)
• Therapeutic trial: 8-12 weeks at therapeutic dose before declaring treatment failure
• Maintenance: Continue treatment 6-12 months after symptom remission; longer for recurrent cases
• Discontinuation: Taper gradually over 2-4 weeks to minimize discontinuation syndrome

Common SSRI/SNRI Side Effects

• Gastrointestinal: nausea, diarrhea (often transient, first 1-2 weeks)
• CNS: headache, insomnia or somnolence, activation/jitteriness
• Sexual: decreased libido, delayed ejaculation, anorgasmia
• Other: sweating, tremor, weight changes

4. FDA Black Box Warning — Suicidality

Risk Data

• Approximately 2-fold increased risk of suicidal ideation in patients under 24 years receiving antidepressants vs placebo
• No increased risk in adults aged 25-64
• Slight protective effect in adults ≥65 years
• Risk is highest in the first month of treatment and during dose adjustments

Required Monitoring Protocol

Documentation Requirements

Obtain and document informed consent including:

• Discussion of the black box warning
• Risk-benefit analysis specific to the patient's age and condition
• Monitoring plan and schedule
• Crisis resources and safety planning
• Family involvement when appropriate

5. Second-Line Agents

When first-line agents are ineffective, poorly tolerated, or contraindicated, these alternatives may be considered.

Buspirone

• Indication: GAD (FDA-approved)
• Dosing: 15-60 mg/day in divided doses (BID-TID)
• Start: 7.5 mg BID, titrate by 5 mg every 2-3 days
• Onset: 2-4 weeks for full effect
• Advantages: No abuse potential, no sedation, minimal sexual side effects
• Limitations: NOT effective for panic disorder; requires TID dosing; delayed onset

Hydroxyzine

• Indication: Acute anxiety, prn use (off-label for chronic anxiety)
• Dosing: 25-100 mg/day or PRN
• Onset: 15-30 minutes
• Advantages: Rapid onset, no abuse potential, useful in SUD population
• Side effects: Sedation, anticholinergic effects, QT prolongation risk

Gabapentin

• Indication: Off-label for GAD, social anxiety
• Dosing: 900-3600 mg/day in divided doses
• Start: 300 mg TID, titrate by 300 mg every 3-7 days
• Evidence: Moderate; small RCTs show benefit in GAD
• Advantages: No hepatic metabolism, minimal drug interactions
• Limitations: Variable bioavailability; Schedule V controlled substance

Pregabalin

• Indication: GAD (approved in Europe), off-label in US
• Dosing: 150-600 mg/day in divided doses (BID or TID)
• Onset: 1 week (faster than SSRIs)
• Evidence: Good evidence for GAD; effect size similar to SSRIs
• Side effects: Dizziness, somnolence, weight gain, peripheral edema
• Note: Schedule V controlled substance; abuse potential in some populations

6. Benzodiazepine Role

Appropriate Use

• Short-term bridge: ≤4 weeks during SSRI initiation for severe symptoms
• Acute panic: PRN for infrequent panic attacks (rarely appropriate)
• Situational use: Specific phobia exposure (e.g., flying)
• Acute crisis: Brief stabilization during psychiatric emergency

Common Agents

Contraindications

Per SAMHSA guidelines, avoid or use extreme caution with:

• History of substance use disorder (especially alcohol, opioids)
• Current opioid prescription (overdose risk)
• Sleep apnea or chronic respiratory conditions
• Elderly patients (fall risk, cognitive effects)
• Pregnancy (risk of neonatal withdrawal, cleft lip/palate)

Monitoring Requirements

• Document rationale for use and treatment duration
• Check state PDMP before prescribing
• Monitor for tolerance and dose escalation
• Plan for discontinuation strategy from day one
• Assess for withdrawal symptoms between doses

Discontinuation

Gradual taper required to avoid withdrawal. For long-term users, reduce by 10-25% every 1-2 weeks. Symptoms of withdrawal include rebound anxiety, insomnia, tremor, seizures (rare), and delirium.

7. Psychotherapy Evidence

Psychological interventions are first-line treatments for anxiety disorders, either alone or combined with pharmacotherapy.

Cognitive Behavioral Therapy (CBT)

Gold standard psychotherapy for anxiety disorders with strong evidence base.

• Effect sizes: d = 0.80-1.3 across anxiety disorders (large effect)
• Duration: 12-20 weekly sessions typical
• Key components:
• Psychoeducation about anxiety
• Cognitive restructuring of anxious thoughts
• Behavioral activation and exposure
• Relaxation and coping skills training

Exposure and Response Prevention (ERP)

Specific CBT variant for:

• Specific phobias: Graduated exposure to feared stimuli
• Panic disorder: Interoceptive exposure to bodily sensations
• Social anxiety: Social exposure exercises

Exposure hierarchy constructed collaboratively; begins with moderately anxiety-provoking items and progresses systematically.

Acceptance and Commitment Therapy (ACT)

Third-wave CBT approach with equivalent efficacy to traditional CBT in multiple RCTs.

• Focuses on acceptance of anxious thoughts rather than control
• Values-based action in presence of anxiety
• Mindfulness and cognitive defusion techniques
• Particularly effective for generalized anxiety

Mindfulness-Based Interventions

• MBSR (Mindfulness-Based Stress Reduction): 8-week group program
• MBCT (Mindfulness-Based Cognitive Therapy): Prevents relapse
• Moderate effect sizes for anxiety reduction
• May be combined with CBT or used as maintenance treatment

Combined Treatment vs Monotherapy

Therapist Qualifications

• Licensed mental health professional (PhD, PsyD, LCSW, LPC)
• Training in CBT protocols for anxiety disorders
• Experience with exposure-based treatments
• Adherence to manualized treatments improves outcomes

8. Treatment Algorithms

Algorithm A: GAD First Presentation

Algorithm B: Treatment-Resistant Anxiety

Algorithm C: Anxiety with Comorbid Depression

Algorithm D: Anxiety with Substance Use Disorder

9. Special Populations

Pregnancy and Lactation

• Preferred agents: Sertraline and fluoxetine have the best pregnancy safety data
• Risk-benefit discussion: Document informed consent regarding medication use in pregnancy
• Untreated anxiety risks: Preterm birth, low birth weight, maternal self-care neglect
• Neonatal adaptation syndrome: Irritability, feeding difficulties, respiratory distress; occurs in 10-30% of neonates exposed to SSRIs in third trimester
• Breastfeeding: Sertraline preferred due to low infant exposure; monitor for sedation, poor feeding

Elderly Patients (≥65 years)

• Pharmacokinetic changes: Reduced hepatic metabolism, increased sensitivity to CNS effects
• Preferred agents: Escitalopram, sertraline (lower drug interaction potential)
• Dosing: Start at 50% of adult dose, slower titration
• Monitoring: Assess for falls, cognitive changes, orthostatic hypotension
• Medical comorbidity: Higher rates of cardiovascular disease may limit agent selection

Substance Use Disorder Comorbidity

• Benzodiazepines: Generally contraindicated due to abuse potential and overdose risk
• Preferred agents: SSRIs, buspirone, hydroxyzine (no abuse potential)
• Concurrent therapy: CBT addresses both anxiety and substance use
• Screening: Use AUDIT-C for alcohol, urine drug screen when appropriate
• Collaboration: Coordinate with addiction medicine specialists

Pediatric/Adolescent Patients

• Black box warning: Enhanced monitoring required for patients <24 years
• Evidence: SSRIs have efficacy data for pediatric anxiety; fluoxetine and sertraline FDA-approved
• Psychotherapy: CBT first-line for mild-moderate cases
• Family involvement: Essential component of treatment
• School accommodation: May need 504 plan or IEP modifications

10. Measurement-Based Care

Systematic use of validated symptom measures improves outcomes and informs clinical decision-making.

GAD-7 Administration Protocol

• Administer at every visit for active treatment
• Use paper or electronic administration
• Score before clinician enters room for objective baseline
• Track scores graphically to visualize trajectory

Interpreting Change Scores

Response vs Remission Definitions

• Response: ≥50% reduction in baseline symptom score
• Partial response: 25-49% reduction
• Remission: GAD-7 <5 (minimal symptoms)
• Functional recovery: Symptom remission + return to premorbid functioning

Step-Up Criteria

Consider treatment escalation if:

• Inadequate response after 8 weeks at therapeutic dose
• Persistent functional impairment
• Patient preference for more aggressive treatment
• Emergence of suicidal ideation

Step-Down Criteria

Consider maintenance dose reduction if:

• Remission maintained for 6+ months
• No active psychosocial stressors
• Strong coping skills demonstrated
• Patient preference

11. Documentation Templates

Template A: Anxiety Follow-Up Progress Note

Template B: SSRI Informed Consent

Template C: Psychiatric Referral Letter

12. Referral Criteria

Refer to Psychiatry

• Treatment resistance: Failure of ≥2 adequate trials of first-line medications
• Diagnostic complexity: Uncertain diagnosis, atypical presentation, suspected bipolar disorder
• Safety concerns: Active suicidal ideation with plan or intent, self-injurious behavior
• Severe impairment: Unable to work, significant functional decline, need for disability evaluation
• Psychotic features: Any evidence of hallucinations or delusions
• Complex medical comorbidity: Significant drug interactions, renal/hepatic impairment requiring specialized dosing
• Request for specific treatments: ECT, TMS, ketamine, MAOIs

Refer for Psychotherapy

• Patient preference for non-pharmacological treatment
• Mild-moderate severity with good motivation
• Specific phobias requiring exposure therapy
• Panic disorder with avoidance requiring ERP
• Social anxiety requiring social skills training
• Comorbid PTSD requiring trauma-focused therapy

Crisis Resources